AstraZeneca Pharmaceuticals LP

Overview

AstraZeneca Pharmaceuticals LP is a global, science-led biopharmaceutical company at the forefront of innovative research across various therapeutic areas. It is a subsidiary of AstraZeneca PLC.

Therapeutic areas

OncologyCardiovascularRenal & MetabolismRespiratoryImmunologyInfection & Vaccines

API / Drug Master Files

AstraZeneca Pharmaceuticals LP holds 5 active (9 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

  • AZD2292Active2022-10-21
  • BUDESONIDEActive2018-10-10
  • GOSERELIN ACETATE IMPLANTActive2017-04-21
  • GOSERELIN ACETATEActive2017-04-21
  • METOPROLOL SUCCINATE EXTENDED RELEASE TABLETSActive2016-12-05
  • METOPROLOL SUCCINATE EXTENDED RELEASE/HYDROCHLOROTHIAZIDE 25/12.5,50/12.5 AND100/12.5 TABLETSInactive2014-05-21
  • LISINOPRIL BULK DRUGInactive1994-04-08
  • ATENOLOL ACETATEInactive1987-08-06
  • ATENOLOLInactive1987-03-30

FDA compliance signals

20 FDA enforcement records linked to this company.

  • 4832024-05-31

    Investigations of discrepancies, failures

  • 4832024-05-31

    Complete Test Data

  • 4832024-05-31

    Procedures not in writing, fully followed

  • 4832024-05-31

    Complaint Handling Procedure

  • 4832023-09-19

    Written in-process control procedures

  • 4832023-09-19

    Complete Test Data

  • warning_letter2023-08-04

    FDA Warning Letter (drug product)

  • 4832022-07-22

    Extent of discrepancy, failure investigations

  • 4832022-07-22

    Procedures for sterile drug products

  • 4832022-07-22

    Equipment Design, Size and Location

  • recall — Class III2018-03-14

    Failed Impurities/Degradation Specifications; elevated levels of quality attribute Form L (polymorph).

  • 4832018-01-30

    Late submission of 15-day report

  • 4832017-08-24

    Complaint Handling Procedure

  • 4832017-08-24

    Procedures not in writing, fully followed

  • recall — Class I2017-07-19

    Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.